

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number  
**WO 01/95944 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 47/48**

(21) International Application Number: PCT/US01/18869

(22) International Filing Date: 12 June 2001 (12.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/211,036 12 June 2000 (12.06.2000) US

(71) Applicant and

(72) Inventor: **MILLS, Randell, L.** [US/US]; 493 Old Trenton Road, Cranbury, NJ 08512-5601 (US).

(74) Agents: **DECONTI, Giulio, A., Jr.** et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/95944 A2**

(54) Title: PRO DRUGS FOR SELECTIVE DRUG DELIVERY

(57) Abstract: Prodrug compounds capable of permeating a desired biological compartment and releasing a biologically active molecule in active form to effect a therapeutic functional change in the compartment to which it is introduced.

## PRO DRUGS FOR SELECTIVE DRUG DELIVERY

### RELATED APPLICATIONS

This application claims the benefit under 35 USC 119(e) of prior-filed provisional patent application No. 60/211,036, filed June 12, 2000, entitled "Pro Drugs  
5 for Selective Drug Delivery". This application is also related to U.S. Patent Nos. 5,428,163 and 5,773,592. The entire content of the above-referenced applications are incorporated herein by this reference.

### BACKGROUND OF THE INVENTION

The effects of the preponderance of drugs result from their interaction with  
10 functional macromolecular components of the organism. Such interaction alters the function of the pertinent cellular component and thereby initiates the series of biochemical and physiological changes that are characteristic of the response to the drug. The term "receptor" denotes the component of the organism with which the chemical agent interacts. There are fundamental corollaries to the statement that the receptor for a  
15 drug can be any functional macromolecular component of the organism. One is that a drug is potentially capable of altering the rate at which any bodily function proceeds; a second is that, by virtue of interactions with specific receptors, drugs do not create effects but merely modulate the rates of ongoing functions. A simple pharmacological dictum thus states that a drug cannot impart a new function to a cell. Functional changes  
20 due to a drug result from either enhancement or inhibition of the unperturbed rate. Furthermore, a drug that has no direct action can cause a functional change by competition for a binding site with another, active regulatory ligand of the receptor. Drugs are termed agonists when they cause effects as a result of direct alteration of the fundamental properties of the receptor with which they interact. Compounds that are  
25 themselves devoid of intrinsic pharmacological activity, but cause effects by inhibition of the action of a specific agonist (e.g. by competition for agonist binding sites) are designated as antagonists.

At least from a numerical standpoint, the proteins of the cell form the most important class of drug receptors. Examples include the enzymes of crucial metabolic or  
30 regulatory pathways (e.g., tyrosine hydroxylase; 3-hydroxy-3-methylglutaryl-CoA reductase). Of equal interest are proteins involved in transport processes (e.g.  $\text{Ca}^{2+}$ -ATPase;  $\text{Na}^{+}$ - $\text{K}^{+}$ -ATPase) or those that are protein kinases which activate other proteins as a consequence of their binding a secondary messenger such as cAMP. Specific

binding properties of other cellular constituents can be exploited. Thus, nucleic acids are important drug receptors, particularly for chemotherapeutic approaches to the control of malignancy, and plant lectins shown remarkable specificity for recognition of specific carbohydrate residues in polysaccharides and glycoproteins. Small ions such as  $\text{Ca}^{2+}$  which can function as a regulatory ion or  $\text{Fe}^{2+}$  which can serve as an essential enzymatic cofactor can be exploited as drug receptors. And, drugs can also produce a functional change by a nonreceptor-mediated action. Certain drugs that are structural analogues of normal biological constituents may be incorporated into cellular components and thereby alter their function. This has been termed a "counterfeit incorporation mechanism" and has been implemented with analogues of purines and pyrimidines that can be incorporated into nucleic acids and that have utility in cancer chemotherapy and that have antiviral activity. Also, specific constituents of pathogens can be exploited as receptors. For example, the electron carriers of bacteria can serve as receptors as described U.S. Application No. 948,326, which is incorporated herein by reference, and the replicative enzymes of viruses can be serve as receptors for the virus HIV. Many compounds are known which have receptor or nonreceptor mediated *in vitro* activity as appears in *The Handbook of Enzyme Inhibitors*, Mahendra Kumor Jain, 1982, Wiley Interscience, New York, incorporated herein by reference. However, only a small percentage produce the desired functional change *in vivo* or have a high therapeutic ratio, because they are toxic in their free form; they are rapidly inactivated or excreted; or, they cannot obtain access to their target receptor or site of action because they are impermeant to cells or biological barriers such as the blood brain barrier due to unfavorable energetics due, for example, to the possession of polar or charge groups; or, they are toxic as a consequence of being nonselective with regards to their access to and action with receptors in one biological environment or compartment relative to another. In these cases, compounds which demonstrate *in vitro* efficacy are ineffective therapeutics.

### SUMMARY OF THE INVENTION

The present disclosure relates to chemical compositions and methods for delivering biologically active agents to a biological compartment. In an embodiment, the invention relates to a chemical compound having the formula A-B, where A is a moiety capable of receiving energy and B is a biologically active agent covalently

bonded to B, wherein the bond between A and B is capable of heterolytic cleavage upon reception of energy by A.

In an advantageous embodiment, the energy causes A to achieve an excited state, the relaxation of which causes heterolytic cleavage of the bond between A and B. In  
5 another embodiment, A is a photochromic or thermochromic moiety. In yet another embodiment, the chemical compound is 1-phosphonoformate,1,5-di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene.

The invention also pertains to a method for selectively delivering a biologically active agent to a biological compartment, which comprises introducing a chemical  
10 compound having the formula A-B, where A is a carrier moiety and B is the biologically active agent, into a biological compartment and exposing the chemical compound to an energy sufficient to cause heterolytic cleavage of the bond between A and B, thereby releasing B from A.

#### DETAILED DESCRIPTION OF THE INVENTION

15 The invention relates to a chemical compound having the formula A-B, where A is a moiety capable of receiving energy and B is a biologically active agent covalently bonded to B, wherein the bond between A and B is capable of heterolytic cleavage upon reception of energy by A.

In a preferred embodiment, the chemical compound is a prodrug, e.g., that  
20 permeates the desired biological compartment and undergoes release of a biologically active agent, in an active form, inside of the desired compartment. In a further embodiment, the prodrug achieves a greater therapeutic effect or therapeutic ratio relative to the free drug alone as a consequence of altered pharmacokinetics or pharmacodynamics (such as a desirable kinetics of release, a resistance to inactivation or  
25 excretion, greater solubility, enhanced absorption, a diminished toxicity, or greater access to the cellular or biological compartment which is the site of action of the drug).

In an advantageous embodiment, A is a photochromic or thermochromic molecule, and B is a biologically active agent such as a drug moiety. In yet another embodiment, A comprises a cationic dye which demonstrates photochromic behavior  
30 with electromagnetic radiation and bleaching agents. Some examples of cationic dyes which can be used for A are di or triarylmethane dyes, triarylmethane lactone or cyclic ether dyes, cationic indoles, pyronines, phthaleins, oxazines, thiazines, acridines,


phenazines, anthocyanidins, cationic polymethine dyes, azo or diazopolymethines, styryls, cyanines, hemicyanines, and dialkylaminopolyenes.

In a preferred embodiment, the chemical compound is a luminide. A luminide comprises a universal carrier molecule linked to one or more of virtually any  
5 biologically active agent including known pharmaceuticals and pesticides. The luminide conjugate potentiates delivery to the desired biological compartment and potentiates intracellular uptake of the biologically active agent which breaks apart due to a reversible bond between the carrier moiety and the biologically active agent to result in release of the free biologically active agent, allowing the desired pharmacological effect  
10 to occur. An embodiment of a luminide is a cellular permeant prodrug where intracellular drug release occurs when the prodrug undergoes heterolytic cleavage of the bond between a drug moiety and a carrier moiety. In another embodiment, the luminide is a two-part molecule where each part is a functionality with a defined purpose.

An exemplary luminide is of the structure A-B, where A represents a  
15 functionality which forms a reversible bond with B, which is released through heterolytic cleavage of the covalent bond of A with B. B is, in an embodiment, a drug moiety which is released in its free form into the environment. The free drug moiety effects a therapeutic functional change in the system to which it is introduced. Such mechanisms may include receptor mediated mechanisms including reversible and  
20 irreversible competitive agonism or antagonism, e.g., a molecule known as a "suicide substrate", a transition state analogue, or a noncompetitive or uncompetitive agonism or antagonism, or the mechanism may be a nonreceptor mediated mechanism such as a "counterfeit incorporation mechanism". The heterolytic cleavage releases the drug moiety into the desired compartment in active form to effect a greater therapeutic effect  
25 or therapeutic ratio relative to the free drug moiety alone as a consequence of altered pharmacokinetics or pharmacodynamics such as a desirable kinetics of release, a resistance to inactivation or excretion, greater solubility, enhanced absorption, a diminished toxicity, or greater access to the cellular or biological compartment which is the site of action of the drug moiety. In an embodiment, the B moiety is a bleaching  
30 agent (a molecule which covalently bonds to A, the carrier moiety of the Luminide such as a photochromic functionality). Such agents comprise essentially any nucleophilic group including phosphate, sulfide, sulfite, sulfate, carboxylate, hydroxyl, or amine.

The invention also pertains to a method for selectively delivering a biologically active agent to a biological compartment, which comprises introducing a chemical compound having the formula A-B, where A is a carrier moiety and B is the biologically active agent, into a biological compartment and exposing the chemical compound to an energy sufficient to cause heterolytic cleavage of the bond between A and B, thereby releasing B from A.

In another embodiment, effective drug delivery is achieved based on the stability of the A-B reversible bond which has a sufficient stability (i.e., a long enough half-life) to permit the prodrug to penetrate the desired biological compartment before the drug moiety is released through heterolytic cleavage of the A-B bond. In another embodiment, the mechanism of drug delivery comprises a dynamic equilibrium between B (drug moiety) bound and unbound to A (carrier moiety). The dynamic equilibrium of the carrier moiety and drug moiety to form the prodrug is:



The prodrug penetrates the desired biological compartment wherein the release occurs. The drug moiety may become trapped inside the desired biological compartment. Thus, the concentration of drug moiety increases over time due to the dynamic transport by the carrier moiety which forms a labile product with the drug moiety.

A luminide may comprise a hybrid molecule of a specified biologically active agent having the optimal structure to achieve the highest therapeutic ratio and a carrier which is modified to achieve optimal bioavailability for a given drug. Thus, the physicochemical properties of a prodrug which change its bioavailability can be manipulated without altering the optimal drug structure. Luminide technology is applicable to essentially all biologically active agents. Luminides may be used in any one of the following uses: antilipidemic drugs, anticholesterol drugs, anticontraceptive agents, anticoagulants, anti-inflammatory agents, immuno-suppressive agents, antiarrhythmic agents, antineoplastic drugs, antihypertensive drugs, epinephrine blocking agents, cardiac inotropic drugs, antidepressant drugs, diuretics, antifungal agents, antibacterial agents, anxiolytic agents, sedatives, muscle relaxants, anticonvulsants, agents for the treatment of ulcer disease, agents for the treatment of asthma and hypersensitivity reactions, antithromboembolytic agents, agents for the treatment of muscular dystrophy,

agents to effect a therapeutic abortion, agents for the treatment of anemia, agents to improve allograft survival, agents for the treatment of disorders of purine metabolism, agents for the treatment of ischemic heart disease, agents for the treatment of opiate withdrawal, agents which activate the effects of secondary messengers, including  
5 inositol triphosphate, agents to block spinal reflexes, antiviral agents (including agents for the treatment of AIDS), pesticide applications, herbicide applications, and veterinary applications.

In an embodiment, the A moiety may be a photochromic or thermochromic molecule, e.g., the A moieties described in Table II of U.S. Patent No. 5,773,592. An  
10 exemplary A moiety is a polymethine dye or triarylmethane dye covalently bound to B. The B moiety may be any biologically active agent which covalently binds to the A moiety (e.g., as a bleaching reaction,) and wherein the bond between A and B is reversible such that the heterolytic cleavage of the covalent bond between A and B may occur inside of the desired biological compartment such as an intracellular compartment,  
15 thereby releasing B. Exemplary B moieties are shown in Table 2 herein. Phosphonoformate (Foscarnet), an HIV-reverse transcriptase inhibitor, is an exemplary B moiety. Exemplary B moieties can also be found in Table 3 and the References at column 161 to 170 of US Patent No. 5,773,592.

Some examples of B moieties that are antihypertensive agents are tyrosine  
20 hydroxylase inhibitors such as 3,5-diiodo-4-hydrobenzoic acid; dopamine B-hydroxylase inhibitors such as mimosine and 2-mercaptoethylamine; dopa decarboxylase inhibitors such as D,L-hydrazino- $\alpha$ -methyldopa; and histidine decarboxylation inhibitors such as NSD 1055.

Some examples of B moieties that may be either sedatives, muscle relaxants, or  
25 anticonvulsants are neurotransmitters such as  $\gamma$ -aminobutyric acid; 2-oxoglutarate, aminotransferase inhibitors such as gabaculine and N-(5'-phosphopyridoxyl-4-aminobutyric acid; GABA release enhancers such as baclofen; and GABA uptake inhibitors such as trans-4-aminocrotonic acid. Some examples of B moieties that are anxiolytics are 2-oxoglutarate aminotransferase inhibitors such as gabaculine and N-(5'-  
30 phosphopyridoxyl-4-aminobutyric acid; GABA release enhancers such as baclofen; and GABA uptake inhibitors such as trans-4-aminocrotonic acid.

Some examples of B moieties that are anticholesterol agents are HMG-CoA reductase inhibitors such as compactin and 3-hydroxy-3methylglutarate. Some examples of B moieties that are antifungal agents are class II aldolase inhibitors such as p-glycolohydroxamate and chitin synthetase inhibitors such as polyoxin D. An example of  
5 a B moiety that is an antibacterial agent is p-glycolohydroxamate, a class II aldolase inhibitor. An example of a B moiety that is an antineoplastic agent is the aspartate transcarbamylase inhibitor N-(phosphonacetyl)-L-asparatate.





An exemplary A moiety is 1,5-di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene , which is shown in Table 1.



| Table 1: Exemplary A Moiety  |           |
|--|-----------|
| Name   | Structure |
| 1,5-di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene |           |

| Table 2: Exemplary B Moieties  |   |
|--------------------------------|---|
| Name                           | Structure   |
| phosphonoformate               |   |
| 3,5-diiodo-4-hydrobenzoic acid |   |
| $\gamma$ -aminobutyric acid    | $\text{H}_2\text{NCH}_2\text{CH}_2\text{CH}_2\text{COOH}$ |
| gabaculine                     |   |

| Table 2: Exemplary B Moieties              |   |
|--|---|
| Name                                       | Structure   |
| N-(5'-phosphopyridoxyl-4-aminobutyric acid | <p>The structure shows a pyridine ring with a methyl group at the 3-position and a hydroxyl group at the 4-position. At the 5-position, there is a -CH<sub>2</sub> group connected to a phosphate group (-CH<sub>2</sub>OP(=O)(OH)OH). At the 6-position, there is a -CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>COOH group.</p> |
| baclofen                                   | <p>The structure shows a benzene ring with a chlorine atom at the 4-position and a -CH(NH<sub>2</sub>)CH<sub>2</sub>CH<sub>2</sub>COOH group at the 1-position.</p>   |
| trans-4-aminocrotonic acid                 | $\text{H}_2\text{NCH}_2\text{CH}=\text{CHCOOH}$   |
| compactin                                  | <p>The structure shows a complex polycyclic molecule. It features a fused ring system with a methyl group and a hydroxyl group. A side chain includes a carboxylic acid group, a hydroxyl group, and an ester linkage to a branched alkyl chain.</p>  |
| 3-hydroxy-3-methylglutarate                | <p>The structure shows a central carbon atom bonded to a hydroxyl group, a methyl group, and two carboxymethyl groups (-CH<sub>2</sub>COOH).</p>  |
| P-glycolohydroxamate                       | <p>The structure shows a phosphate group (O=P(O<sup>-</sup>)<sub>2</sub>) connected via an oxygen atom to a -CH<sub>2</sub>- group, which is then connected to a carbon atom double-bonded to a nitrogen atom (C=N-OH) and single-bonded to an oxygen atom (C=O-O<sup>-</sup>).</p>   |
| N-(phosphonacetyl)-l-aspartate             | <p>The structure shows an aspartate moiety (a central carbon bonded to a carboxylate group, an amino group, and a carboxymethyl group) where the amino group is part of an amide linkage to an acetyl group (-C(=O)-CH<sub>2</sub>-). The acetyl group is further linked to a phosphate group (-P(=O)(O<sup>-</sup>)<sub>2</sub>).</p>          |
| phosphonoacetate                           | <p>The structure shows a phosphate group (O=P(O<sup>-</sup>)<sub>2</sub>) connected via an oxygen atom to a -CH<sub>2</sub>- group, which is then connected to a carboxylate group (-COO<sup>-</sup>).</p>  |

| Table 2: Exemplary B Moieties |  |
|-------------------------------|--|
| Name                          | Structure  |
| mimosine                      |   |
| 2-mercaptoethylamine          | HSCH <sub>2</sub> CH <sub>2</sub> NH <sub>3</sub> <sup>+</sup>                       |
| NSD 1055                      |    |
| polyoxin D                    |   |
| D,L-hydrazino-α-methyldopa    |  |

An exemplary luminide, i.e., A-B compound, is 1-phosphonoformate,1,5-di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene shown in Table 3.

| Table 3   |           |
|---|-----------|
| Name  | Structure |
| 1-phosphonoformate,1,5-di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene |           |

### EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than

5 routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the following claims. The contents of all references, issued patents, and published patent applications cited throughout this application are hereby

incorporated by reference. The appropriate components, processes, and methods of

10 those patents, applications and other documents may be selected for the present invention and embodiments thereof.

## CLAIMS

*What is claimed is:*

1. A chemical compound having the formula A-B, where  
A is a moiety capable of receiving energy; and  
5 B is a biologically active agent covalently bonded to B, wherein  
the bond between A and B is capable of heterolytic cleavage upon  
reception of energy by A.
2. The chemical compound of claim 1, wherein A is a photochromic moiety.
3. The chemical compound of claim 1, wherein A is a  
10 thermochromic moiety.
4. The chemical compound of claim 1, wherein said energy causes A to  
achieve an excited state; and relaxation of said excited state of A causes heterolytic  
cleavage of said covalent bond between A and B.
5. The chemical compound of claim 1, wherein said chemical compound is  
15 1-phosphonoformate, 1,5-di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-  
dimethylaniline)-1,3-pentadiene.
6. The chemical compound of claim 1, wherein A is 1,5-di-(p-N-ethyl-N-  
ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene.
7. The chemical compound of claim 1, wherein A comprises a cationic dye  
20 which demonstrates photochromic behavior with electromagnetic radiation and  
bleaching agents.
8. The chemical compound of claim 7, wherein said cationic dye is selected  
from the group consisting of di or triarylmethane dye, a triarylmethane lactone or a  
cyclic ether dye, a cationic indole, a pyronine, a phthalein, an oxazine, a thiazine, an

acridine, a phenazine, an anthocyanidin, a cationic polymethine dye, an azo or a diazopolymethine, a styryl, a cyanine, a hemicyanine, and a dialkylaminopolyene.

9. The chemical compound of claim 1, wherein B is a drug moiety which effects a therapeutic functional change by a mechanism selected from the group  
5 consisting of receptor mediated mechanisms and nonreceptor mediated mechanisms.

10. The chemical compound of claim 1, wherein B is selected from the group consisting of antilipidemic drugs, anticholesterol drugs, anticoagulants, antihypertensive drugs, cardiac inotropic drugs, antineoplastic drugs, antidepressant drugs, agents for the treatment of asthma and hypersensitivity reactions, diuretics, antifungal agents,  
10 antibacterial drugs, anxiolytic agents, sedatives, muscle relaxants, anticonvulsants, agents for the treatment of ischemic heart disease, agents which activate the effects of secondary messengers, agents to block spinal reflexes, and antiviral agents.

11. The chemical compound of claim 1, wherein B is selected from the group consisting of 3,5-diiodo-4-hydroxybenzoic acid,  $\gamma$ -aminobutyric acid, gabaculine, N-(5'-  
15 phosphopyridoxyl)-4-aminobutyric acid, baclofen, trans-4-aminocrotonic acid, compactin, 3-hydroxy-3-methylglutarate, p-glycolohydroxamate, N-(phosphonoacetyl)-L-aspartate, phosphonoacetate, mimosine, 2-mercaptoethylamine, NSD 1055, polyoxin D, D,L-hydrazino- $\alpha$ -methyldopa, and phosphonoformate.

12. The chemical compound of claim 1, wherein B is phosphonoacetate or  
20 phosphonoformate (Foscarnet).

13. The chemical compound of claim 1, wherein B is an antihypertensive agent.

14. The chemical compound of claim 13, wherein B is selected from the group consisting of 3,5-diiodo-4-hydroxybenzoic acid, mimosine, D,L-hydrazino- $\alpha$ -methyldopa, and 2-mercaptoethylamine.
15. The chemical compound of claim 1, wherein B is an antiviral agent.
- 5 16. The chemical compound of claim 15, wherein B is selected from the group consisting of phosphonoacetate and phosphonoformate.
17. The chemical compound of claim 1, wherein B is an anticholesterol agent.
18. The chemical compound of claim 17, wherein B is selected from the  
10 group consisting of compactin and 3-hydroxy-3-methylglutarate.
19. The chemical compound of claim 1, wherein B is an anticonvulsant agent.
20. The chemical compound of claim 19, wherein B is selected from the group consisting of gabaculine, N-5'-phosphopyridoxyl-4-aminobutyric acid, baclofen,  
15 trans-4-aminocrotonic acid, and  $\gamma$ -aminobutyric acid.
21. The chemical compound of claim 1, wherein B is an antibacterial or antifungal agent.
22. The chemical compound of claim 21, wherein B is selected from the group consisting of p-glycolohydroxamate and polyoxin D.
- 20 23. The chemical compound of claim 1, wherein B is an antineoplastic agent.
24. The chemical compound of claim 23, wherein B is N-(phosphonoacetyl)-L-aspartate.
25. The chemical compound of claim 1, wherein said chemical compound is covalently bound to a biocompatible polymer to which an enzyme is immobilized.

26. The chemical compound of claim 25, wherein B is insulin and said enzyme is glucose oxidase.

27. The chemical compound of claim 25, wherein B is tissue plasminogen activator and said enzyme is xanthine oxidase.

5 28. A method for selectively delivering a biologically active agent to a biological compartment, which comprises:

introducing a chemical compound having the formula A-B, where A is a carrier moiety and B is a biologically active agent, into said biological compartment; and

10 exposing said chemical compound to an energy sufficient to cause heterolytic cleavage of said bond between A and B, thereby releasing B from A.

29. The method of claim 28, wherein A is a photochromic moiety.

30. The method of claim 28, wherein A is a thermochromic moiety.

31. The method of claim 28, wherein said energy causes A to achieve an  
15 excited state; and relaxation of said excited state of A causes heterolytic cleavage of said covalent bond between A and B.

32. The method of claim 28, wherein said chemical compound is 1-phosphonoformate, 1,5-di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene.

20 33. The method of claim 28, wherein A is 1,5-di-(p-N-ethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene.

34. The method of claim 28, wherein A comprises a cationic dye which demonstrates photochromic behavior with electromagnetic radiation and bleaching agents.



35. The method of claim 34, wherein said cationic dye is a di or triarylmethane dye, a triarylmethane lactone or a cyclic ether dye, a cationic indole, a pyronine, a phthalein, an oxazine, a thiazine, an acridine, a phenazine, an anthocyanidin, a cationic polymethine dye, an azo or a diazopolymethine, a styryl, a  
5 cyanine, a hemicyanine, or a dialkylaminopolyene.

36. The method of claim 28, wherein B is phosphonoformate (Foscarnet).

37. The method of claim 28, wherein B is selected from the group consisting of 3,5-diiodo-4-hydroxybenzoic acid,  $\gamma$ -aminobutyric acid, gabaculine, N-(5'-phosphopyridoxyl)-4-aminobutyric acid, baclofen, trans-4-aminocrotonic acid,  
10 compactin, 3-hydroxy-3-methylglutarate, p-glycolohydroxamate, N-(phosphonoacetyl)-L-aspartate, phosphonoacetate, mimosine, 2-mercaptoethylamine, NSD 1055, polyoxin D, D,L-hydrazino- $\alpha$ -methyldopa, and phosphonoformate.

38. The method of claim 28, wherein B is a drug molecule which effects a therapeutic functional change by a mechanism selected from the group consisting of  
15 receptor mediated mechanisms and nonreceptor mediated mechanisms.

39. The method of claim 28, wherein B is selected from the group consisting of antilipidemic drugs, anticholesterol drugs, anticoagulants, antihypertensive drugs, cardiac inotropic drugs, antineoplastic drugs, antidepressant drugs, agents for the treatment of asthma and hypersensitivity reactions, diuretics, antifungal agents,  
20 antibacterial drugs, anxiolytic agents, sedatives, muscle relaxants, anticonvulsants, agents for the treatment of ischemic heart disease, agents which activate the effects of secondary messengers, agents to block spinal reflexes, and antiviral agents.

40. The method of claim 28, wherein B is an antihypertensive agent.

41. The method of claim 40, wherein B is selected from the group consisting of 3,5-diiodo-4-hydroxybenzoic acid, mimosine, D,L-hydrazino- $\alpha$ -methyldopa, and 2-mercaptoethylamine.
42. The method of claim 28, wherein B is an antiviral agent.
- 5 43. The method of claim 42, wherein B is selected from the group consisting of phosphonoacetate and phosphonoformate.
44. The method of claim 28, wherein B is an anticholesterol agent.
45. The method of claim 44, wherein B is selected from the group consisting of compactin and 3-hydroxy-3-methylglutarate.
- 10 46. The method of claim 28, wherein B is an anticonvulsant agent.
47. The method of claim 46, wherein B is selected from the group consisting of gabaculine, N-5'-phosphopyridoxyl-4-aminobutyric acid, baclofen, trans-4-aminocrotonic acid, and  $\gamma$ -aminobutyric acid.
48. The method of claim 28, wherein B is an antibacterial or antifungal agent.
- 15 49. The method of claim 48, wherein B is selected from the group consisting of p-glycolohydroxamate and polyoxin D.
50. The method of claim 28, wherein B is an antineoplastic agent.
51. The method of claim 50, wherein B is N-(phosphonoacetyl)-L-aspartate.
52. The method of claim 28, wherein said chemical compound is covalently
- 20 bound to a biocompatible polymer to which an enzyme is immobilized.
53. The method of claim 52, wherein B is insulin and said enzyme is glucose oxidase.
54. The method of claim 52, wherein B is tissue plasminogen activator and said enzyme is xanthine oxidase.

55. The method of claim 28, wherein said energy is electromagnetic radiation.

56. The method of claim 28, wherein said energy is heat energy.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number  
**WO 01/095944 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 41/00**,  
47/48

(21) International Application Number: PCT/US01/18869

(22) International Filing Date: 12 June 2001 (12.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/211,036 12 June 2000 (12.06.2000) US

(71) Applicant and

(72) Inventor: **MILLS, Randell, L.** [US/US]; 493 Old Trenton  
Road, Cranbury, NJ 08512-5601 (US).

(74) Agents: **DECONTI, Giulio, A., Jr.** et al.; Lahive & Cock-  
field, LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:

8 August 2002

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 01/095944 A3**

(54) Title: PHOTOCLEAVABLE PRODRUGS FOR SELECTIVE DRUG DELIVERY

(57) Abstract: Prodrug compounds capable of permeating a desired biological compartment and releasing a biologically active molecule in active form through photocleavage to effect a therapeutic functional change in the compartment to which it is introduced.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/18869

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K41/00 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.                         |
|------------|--|---|
| X          | WO 94 09826 A (MEDIPRO SCIENCES LIMITED)<br>11 May 1994 (1994-05-11)<br><br>page 20, line 1 - line 30<br>claims 1-18<br><br>---                            | 1,2,9,<br>10,23,<br>28,29,<br>31,38,<br>39,50 |
| X          | US 5 773 592 A (RANDER LEE MILLS)<br>30 June 1998 (1998-06-30)<br>cited in the application<br>column 7 -column 74; tables II-III<br>claims 1-26<br><br>--- | 1-56  |
| X          | US 5 428 163 A (RANDEL L. MILLS)<br>27 June 1995 (1995-06-27)<br>cited in the application<br>column 8 -column 67<br><br>---<br><br>-/--                    | 1-56  |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

8 February 2002

Date of mailing of the international search report

19/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/18869

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.                         |
|------------|--|---|
| X          | WO 86 00527 A (DANA-FARBER CANCER INSTITUTE) 30 January 1986 (1986-01-30)<br><br>claims 1-24<br>page 7, line 1 - line 18<br>-----  | 1,2,9,<br>10,23,<br>28,29,<br>31,38,<br>39,50 |
| X          | GOLDMACHER V S ET AL: "PHOTOACTIVATION OF TOXIN CONJUGATES"<br>BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US,<br>vol. 3, no. 2, 1 March 1992 (1992-03-01),<br>pages 104-107, XP000262168<br>ISSN: 1043-1802<br>abstract<br>----- | 1,2,9,<br>10,23,<br>28,29,<br>31,38,<br>39,50 |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/18869

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---|---------------------|--|--|
| WO 9409826                                | A | 11-05-1994          | US 5482719 A<br>AU 5414194 A<br>CA 2175479 A1<br>WO 9409826 A2   | 09-01-1996<br>24-05-1994<br>11-05-1994<br>11-05-1994   |
| US 5773592                                | A | 30-06-1998          | US 5428163 A<br>AT 187776 T<br>AU 3445489 A<br>CN 1047075 A<br>DE 68929117 D1<br>DE 68929117 T2<br>EP 0414730 A1<br>JP 3025817 B2<br>JP 3505574 T<br>WO 8909833 A1 | 27-06-1995<br>15-01-2000<br>03-11-1989<br>21-11-1990<br>20-01-2000<br>24-08-2000<br>06-03-1991<br>27-03-2000<br>05-12-1991<br>19-10-1989 |
| US 5428163                                | A | 27-06-1995          | US 5773592 A   | 30-06-1998   |
| WO 8600527                                | A | 30-01-1986          | US 4625014 A<br>CA 1243015 A1<br>DE 3582130 D1<br>EP 0185762 A1<br>JP 6025071 B<br>JP 61502608 T<br>WO 8600527 A1  | 25-11-1986<br>11-10-1988<br>18-04-1991<br>02-07-1986<br>06-04-1994<br>13-11-1986<br>30-01-1986   |